z-logo
open-access-imgOpen Access
<p>Galanin Receptors as Drug Target for Novel Antidepressants: Review</p>
Author(s) -
Desalegn Getnet Demsie,
Birhanetensay Masresha Altaye,
Etsay Weldekidan,
Hagazi Gebremedhin,
Niguse Meles Alema,
Molla Tefera,
Abere Tilahun Bantie
Publication year - 2020
Publication title -
biologics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 38
eISSN - 1177-5491
pISSN - 1177-5475
DOI - 10.2147/btt.s240715
Subject(s) - galanin , receptor , antidepressant , serotonin , neuropeptide , galanin receptor , pharmacology , medicine , neuroscience , endocrinology , biology , hippocampus
Galanin (GAL) is a 29-amino-acid neuropeptide that serves multiple physiological functions throughout the central and peripheral nervous system. Its role involves in a range of physiological and pathological functions including control of food intake, neuro-protection, neuronal regeneration, energy expenditure, reproduction, water balance, mood, nociception and various neuroendocrine functions. The use of currently available antidepressant drugs raises concerns regarding efficacy and onset of action; therefore, the need for antidepressants with novel mechanisms is increasing. Presently, various studies revealed the link between GAL and depression. Attenuation of depressive symptoms is achieved through inhibition of GalR1 and GalR3 and activation of GalR2. However, lack of receptor selectivity of ligands has limited the complete elucidation of effects of different receptors in depression-like behavior. Studies have suggested that GAL enhances the action of selective serotonin reuptake inhibitors (SSRIs) and promotes availability of transcription proteins. This review addresses the role of GAL, GAL receptors (GALRs) ligands including selective peptides, and the mechanism of ligand receptor interaction in attenuating depressive symptoms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here